ジェネリック医薬品のベトナム市場の評価：用途別、タイプ別、ブランド別、投与経路別、流通チャネル別、地域別、機会、予測（2017年～2031年）

ベトナムのジェネリック医薬品の市場規模は、2023年の39億米ドルから2031年に74億2,000万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで8.39％の成長が見込まれます。市場の成長は、ジェネリック医薬品に関連するさまざまな利点とその有効性に関する認知度を高める政府の施策の高まりや、特許の失効、国内における非感染性疾患の脅威の増大などによって支えられています。また、外国企業による投資を促進する政府の支援策や薬事法の導入も市場の成長を支えています。2024年1月、ベトナム保健省は外資系企業により多くのインセンティブと権利を与えるため、同国の薬事法の改正を発表しました。この改正により、投資優遇措置の範囲が拡大され、ジェネリック特殊医薬品やベトナムでのハイテク医薬品製造が含まれるようになっています。また、社会的疾病の制御と予防に必要な医薬品、バイオテクノロジー製品、生物学的製品、ワクチンも含まれます。新条項はまた、外国からの投資、技術移転、ジェネリック特殊医薬品や医薬品原材料の研究および生産などを奨励しています。

ベトナムでは、複数の慢性疾患が流行しているため、手頃な価格の医薬品に対する需要が高まっており、ベトナムのジェネリック医薬品の市場規模を押し上げています。

世界保健機関（WHO）の推計によると、ベトナムでは毎年約11万5,000人が新たにがんで死亡し、16万5,000人が新たにがんに罹患しています。このような疾患や障害に対抗するため、国内でのジェネリック医薬品の利用の促進に向け、政府は製薬産業の発展と拡大、高品質なジェネリック医薬品や革新的な医薬品の生産を支援するさまざまな優遇政策を導入しています。こうした取り組みが市場の拡大を支えています。

さらに、同国の医療部門の急速な拡大や、インフラ開発に向けた投資の増加、必要な医薬品へのアクセスの確保、ジェネリック医薬品に関する大衆の教育の推進も市場の成長を支えています。

新たな規制が市場拡大を後押し

同国の保健省は、医薬品の包装と標示に関する新たな改正を導入し、2024年1月15日に施行しました。この改正には、QRコードやバーコードなどをラベルに統合することが含まれており、ラベルや説明書の電子化、医薬品の効率性の確保、トレーサビリティのサポートなど、厚生省の目標に沿ったものとなっています。この規制はまた、ジェネリック医薬品が先発医薬品の品質と基準に合致するよう、定期的な更新を義務付けています。これらの規制は、ジェネリック医薬品の品質を向上させ、コンプライアンスを確保することで、ジェネリック医薬品に対する人々の信頼を高め、市場の拡大を支援することを目的としています。

非感染性疾患の増加が市場需要を押し上げる

ベトナムでは糖尿病、がん、呼吸器疾患、心血管疾患などの非感染性疾患の患者が増加しており、ベトナムのジェネリック医薬品市場の需要を押し上げています。2022年9月にPLOS ONEで公開された論文によると、非感染性疾患はベトナムの主な死因の1つであり、がん、糖尿病、心血管疾患がもっとも一般的です。同国における非伝染性疾患の負担の増加は、都市化の進行と経済成長によるものであると考えられます。さらに、ベトナムの山岳地帯に住む人々は、地理的な障壁や低い社会経済的地位のために医療サービスへのアクセスが制限されているため、非感染性疾患に対してより脆弱です。そのため、非感染性疾患の脅威が増大し、同国におけるジェネリック医薬品への需要が高まっています。

主要企業と病院との連携が市場成長を支える

慢性疾患と闘う患者のケアの質を向上させるため、市場の主要企業と病院との協力関係が高まっており、今後数年間の市場成長にプラスの影響を与えると予測されます。2024年6月、Vietnam National Cancer HospitalとSandoz Group AGは、ハノイとベトナム全土でがんに苦しむ患者の治療水準を向上させる覚書を締結しました。Sandozは、抗感染症薬やがん治療薬などの分野において、バイオシミラーやジェネリック医薬品を含む安価な医薬品への患者アクセスの向上に取り組んでいます。さらに、同社は2024年3月にHo Chi Minh City Oncology Hospitalと同様のパートナーシップを締結しました。こうした提携により、慢性疾患の患者に対するジェネリック医薬品の供給が促進されることが予測されます。

当レポートでは、ベトナムのジェネリック医薬品市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 ベトナムのジェネリック医薬品市場の見通し（2017年～2031年）

• 市場規模の分析と予測
  • 金額
  • 数量
• 市場シェア分析と予測
  • 用途別
  • タイプ別
  • ブランド別
  • 投与経路別
  • 流通チャネル別
  • 地域別
  • 市場シェア分析：企業別（金額）（上位5社とその他 - 2023年）
• 市場マップ分析（2023年）
  • 用途別
  • タイプ別
  • ブランド別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 需給分析

第6章 輸入と輸出の分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場促進要因
• 市場の課題

第12章 市場の動向と発展

第13章 規制枠組みとイノベーション

• バイオアベイラビリティ/生物学的同等性試験
• 規制当局の承認

第14章 特許の失効

第15章 ケーススタディ

第16章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要企業上位10社の情勢
  • DHG Pharmaceutical Joint-Stock Company
  • Sanofi-Aventis Vietnam Company Limited
  • Imexpharm Corporation
  • TRAPHACO JOINT STOCK COMPANY
  • BIDIPHAR
  • STADA Arzneimittel AG
  • Sandoz Group AG

第17章 戦略的推奨

第18章 当社について、免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Vietnam Generic Drugs Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Vietnam Generic Drugs Market, By Volume, In Number of Prescriptions, 2017-2031F
• Figure 3. Vietnam Generic Drugs Market Share (%), By Application, 2017-2031F
• Figure 4. Vietnam Generic Drugs Market Share (%), By Type, 2017-2031F
• Figure 5. Vietnam Generic Drugs Market Share (%), By Brand, 2017-2031F
• Figure 6. Vietnam Generic Drugs Market Share (%), By Route of Administration, 2017-2031F
• Figure 7. Vietnam Generic Drugs Market Share (%), By Distribution Channel, 2017-2031F
• Figure 8. Vietnam Generic Drugs Market Share (%), By Region, 2017-2031F
• Figure 9. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 10. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 11. By Brand Size Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 12. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Vietnam generic drugs market is projected to witness a CAGR of 8.39% during the forecast period 2024-2031, growing from USD 3.90 billion in 2023 to USD 7.42 billion in 2031. The market's growth is supported by the government's rising measures to increase awareness about the various advantages associated with generics and their efficacy, the expiration of patents, and the growing threat of non-communicable diseases in the country. The market's growth is also supported by supportive government measures and the introduction of pharmacy laws to boost investments by foreign companies. In January 2024, the Ministry of Health in Vietnam released an amendment to the country's Pharmacy Law to give foreign companies more incentives and rights. With the amendment, the scope of investment incentives has been expanded to include generic specialty drugs, and high-tech drug manufacturing in Vietnam. It also includes drugs necessary for controlling and preventing social diseases, biotechnological products, biological products, and vaccines. The new clause also encourages foreign investments, technology transfer, and research and production of generic specialty drugs and pharmaceutical raw materials, among others.

Due to the increasing prevalence of several chronic conditions in the country, the demand for affordable medications is rising, boosting the Vietnam generic drugs market size.

According to the estimates of the World Health Organization (WHO), approximately 115,000 new deaths related to cancer and 165,000 new cases of cancer are recorded every year in Vietnam. To propel the availability of generics in the country to combat such diseases and disorders, the government has introduced various preferential policies to support the development and expansion of the pharmaceutical industry and the production of high-quality generics and innovative drugs. Such efforts are supporting the market's expansion.

Furthermore, the rapid expansion of the country's healthcare sector, increasing investments towards infrastructural development, ensuring the accessibility of required medications, and promoting education among the general population about generics are also supporting the market's growth.

New Regulations Support Market Expansion

The country's Ministry of Health introduced new amendments regarding the packaging and labeling of pharmaceutical products that went into effect on January 15, 2024. The amendments include the integration of QR codes and barcodes, among others, into the labels, aligning with the Ministry of Health's goal for electronic labeling and instructions, ensuring the efficiency of pharmaceutical products, and supporting their traceability. The regulations also require regular updates on generics to ensure that they are in alignment with the quality and standards of the original brand-name drugs. These regulations aim to improve the quality of generic drugs and ensure compliance, enhancing the population's confidence in generic drugs and supporting the market's expansion.

Rising Cases of Non-Communicable Diseases Boost Market Demand

The increasing cases of non-communicable diseases, including diabetes, cancer, respiratory diseases, and cardiovascular diseases in Vietnam, are bolstering the Vietnam generic drugs market demand. According to an article published in PLOS ONE in September 2022, non-communicable diseases are one of the leading causes of death in Vietnam, with cancer, diabetes, and cardiovascular disease being the most common. The growing burden of non-communicable diseases in the country can be attributed to increasing urbanization and economic growth. Furthermore, the individuals living in the mountainous region of the country are more vulnerable to non-communicable diseases due to limited access to healthcare services because of geographical barriers and low socioeconomic status. The increasing threat of non-communicable diseases is thus bolstering the requirement for generic drugs in the country.

Collaborations Between Key Players and Hospitals Support Market Growth

The rising collaborations between the key players of the market and hospitals to improve the quality of care for patients battling chronic conditions are expected to influence the market's growth in the coming years positively. In June 2024, Vietnam National Cancer Hospital and Sandoz Group AG signed a Memorandum of Understanding (MoU) to improve the standard of care for patients suffering from cancer in Hanoi and around the country. Sandoz is committed to improving patient access to affordable medications, including biosimilars and generics, in the field of anti-infectives and oncology, among others. Additionally, the company entered a similar partnership with Ho Chi Minh City Oncology Hospital in March 2024. Such collaborations are expected to boost the availability of generics for patients with chronic conditions.

Biosimilars Hold Significant Market Share

The growth of the segment can be attributed to the increasing preference for lower-cost alternatives due to the rising costs of prescription drugs in Vietnam. The increasing introduction of biosimilars also supports the growth of the Vietnam generic drugs market. In March 2022, Shanghai Henlius Biotech, Inc. collaborated with Getz Pharma Limited to commercialize Handayuan, an adalimumab biosimilar, across several countries in Africa and Asia. The supply and licensing agreement will allow the latter to market the biosimilar in Vietnam, Ukraine, Sri Lanka, Myanmar, Cambodia, Philippines, and Uzbekistan, among others. Such agreements and collaborations are expected to boost the accessibility of biosimilars in Vietnam, supporting the segment's expansion and growth of the Vietnam generic drugs market.

Future Market Scenario (2024-2031F)

As per the Vietnam generic drugs market analysis, the market is expected to witness significant growth in the coming years owing to rising investments in pharmaceutical manufacturing, the growing prevalence of chronic diseases, and increasing government initiatives to bolster the utilization of generics. Additionally, as the market expansion continues, it is expected to provide lucrative growth opportunities for both international and domestic pharmaceutical companies. The increasing measures by the government to ensure the availability of affordable medications are also expected to propel the demand for generic drugs in Vietnam.

Key Players Landscape and Outlook

The increasing investments by the leading market players in modern medicines are supporting the market's expansion. In April 2024, TRAPHACO JOINT STOCK COMPANY announced that they would focus on enhancing their research and development capabilities as well as new technology products and launch their first generic drugs. To facilitate these goals, the company is recruiting external research and development experts and increasing its investments toward enhancing its workforce and internal departments. Such investments are expected to boost the manufacture of generic drugs in Vietnam and provide lucrative growth opportunities to the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Vietnam Generic Drugs Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Application
    • 4.2.1.1. Neurovascular
    • 4.2.1.2. Cardiovascular
    • 4.2.1.3. Dermatology
    • 4.2.1.4. Oncology
    • 4.2.1.5. Diabetology
    • 4.2.1.6. Respiratory
    • 4.2.1.7. Others
  • 4.2.2. By Type
    • 4.2.2.1. Biosimilar Generics
    • 4.2.2.2. Small Molecule Generics
  • 4.2.3. By Brand
    • 4.2.3.1. Branded Generic
    • 4.2.3.2. Pure Generic
  • 4.2.4. By Route of Administration
    • 4.2.4.1. Oral
    • 4.2.4.2. Injectable
    • 4.2.4.3. Topical
    • 4.2.4.4. Others
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital Pharmacy
    • 4.2.5.2. Retail Pharmacy
    • 4.2.5.3. Online Pharmacy
  • 4.2.6. By Region
    • 4.2.6.1. North
    • 4.2.6.2. South
    • 4.2.6.3. Central
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Application
  • 4.3.2. By Type
  • 4.3.3. By Brand
  • 4.3.4. By Route of Administration
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Bioavailability/Bioequivalence Studies
• 13.2. Regulatory Approvals

14. Patent Expiration

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top 10 Market Players
  • 16.3.1. DHG Pharmaceutical Joint-Stock Company
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Sanofi-Aventis Vietnam Company Limited
  • 16.3.3. Imexpharm Corporation
  • 16.3.4. TRAPHACO JOINT STOCK COMPANY
  • 16.3.5. BIDIPHAR
  • 16.3.6. STADA Arzneimittel AG
  • 16.3.7. Sandoz Group AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer